BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$140M |
| 2 |
iShares US Financials ETF
IYF
|
+$119M |
| 3 |
AGN
Allergan plc
AGN
|
+$100M |
| 4 |
Charter Communications
CHTR
|
+$95.1M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$82.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.2B |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$909M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$623M |
| 4 |
Apple
AAPL
|
+$389M |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$369M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.73% |
| 2 | Financials | 5.47% |
| 3 | Healthcare | 4.96% |
| 4 | Consumer Discretionary | 4.64% |
| 5 | Industrials | 3.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3801
CorMedix
CRMD
$557M
| $26.6K | ﹤0.01% |
3,649
+654
| +22% | +$4K |
|
3802
GSI Technology
GSIT
$255M
| $26.5K | ﹤0.01% |
3,743
+1,808
| +93% | +$13.7K |
|
3803
Stagwell
STGW
$2.29B
| $26.3K | ﹤0.01% |
9,469
+417
| +5% | +$1.12K |
|
|
PTN
3804
Palatin Technologies
PTN
$16.8M
| $26.3K | ﹤0.01% |
27
| – | – |
|
|
GSKY
3805
DELISTED
GreenSky, Inc. Class A Common Stock
GSKY
| $26.3K | ﹤0.01% |
2,951
+607
| +26% | +$4.56K |
|
3806
Abeona Therapeutics
ABEO
$425M
| $26.1K | ﹤0.01% |
319
+117
| +58% | +$8.26K |
|
|
GRTS
3807
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $26.1K | ﹤0.01% |
2,908
-508
| -15% | -$4.24K |
|
3808
Escalade
ESCA
$284M
| $25.9K | ﹤0.01% |
2,638
+888
| +51% | +$9.62K |
|
|
VAPO
3809
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $25.8K | ﹤0.01% |
266
+13
| +5% | +$1.1K |
|
3810
Ascent Industries
ACNT
$133M
| $25.7K | ﹤0.01% |
1,994
+636
| +47% | +$8.83K |
|
3811
Flotek Industries
FTK
$1.35B
| $25.6K | ﹤0.01% |
2,135
+652
| +44% | +$7.52K |
|
3812
Banco Santander Chile
BSAC
$16B
| $25.6K | ﹤0.01% |
1,109
+375
| +51% | +$9.32K |
|
|
PVLA
3813
Palvella Therapeutics
PVLA
$2.23B
| $25.4K | ﹤0.01% |
88
-16
| -15% | -$4.44K |
|
3814
Ocular Therapeutix
OCUL
$2.25B
| $25.1K | ﹤0.01% |
6,346
+411
| +7% | +$1.43K |
|
3815
Angi Inc
ANGI
$176M
| $25K | ﹤0.01% |
295
+34
| +13% | +$2.54K |
|
3816
Kiniksa Pharmaceuticals
KNSA
$6.1B
| $24.8K | ﹤0.01% |
2,242
+26
| +1% | +$226 |
|
3817
Spyre Therapeutics
SYRE
$9.18B
| $24.6K | ﹤0.01% |
129
-9
| -7% | -$1.77K |
|
|
NAGE
3818
Niagen Bioscience
NAGE
$242M
| $24.6K | ﹤0.01% |
5,704
-618
| -10% | -$2.2K |
|
3819
Syndax Pharmaceuticals
SNDX
$1.77B
| $24.5K | ﹤0.01% |
2,788
+236
| +9% | +$1.73K |
|
3820
Gencor Industries
GENC
$265M
| $24.5K | ﹤0.01% |
2,097
+648
| +45% | +$7.8K |
|
|
UBX
3821
DELISTED
Unity Biotechnology
UBX
| $24.3K | ﹤0.01% |
337
-72
| -18% | -$5.08K |
|
3822
HF Foods Group
HFFG
$99.2M
| $24.1K | ﹤0.01% |
1,236
+869
| +237% | +$17.3K |
|
|
LITS
3823
Lite Strategy Inc
LITS
$31.4M
| $23.8K | ﹤0.01% |
480
+50
| +12% | +$1.86K |
|
3824
Lexicon Pharmaceuticals
LXRX
$1.05B
| $23.8K | ﹤0.01% |
5,728
-1,986
| -26% | -$7.64K |
|
|
CMRX
3825
DELISTED
Chimerix, Inc.
CMRX
| $23.7K | ﹤0.01% |
11,661
+3,992
| +52% | +$7.36K |
|
Similar funds
BNP Paribas Financial Markets's Q4 2019 Portfolio in Review
As of Q4 2019, BNP Paribas Financial Markets held 4,613 positions worth $54.9B, down 2.5% from $56.3B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
BNP Paribas Financial Markets withdrew a net $10.1B in Q4 2019, closing 185 positions and reducing 1,420 holdings. Its most notable exit was Celgene Corp, an estimated $56.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 7.7% of assets, down from 8.3% a quarter earlier, followed by Financials and Healthcare.
Against the trend, BNP Paribas Financial Markets opened a new position in iShares US Financials ETF worth $124M.
- BNP Paribas Financial Markets's largest Q4 2019 buy was iShares US Financials ETF: 1,800,000 shares worth $124M.
- BNP Paribas Financial Markets added most to Bristol-Myers Squibb in Q4 2019, an estimated $140M increase.
- BNP Paribas Financial Markets's biggest Q4 2019 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.2B.
- BNP Paribas Financial Markets fully exited Celgene Corp in Q4 2019, selling an estimated $56.8M.
- BNP Paribas Financial Markets's ten largest holdings make up 16% of its $54.9B portfolio in Q4 2019.
- BNP Paribas Financial Markets opened 106 new positions and closed 185 in Q4 2019.
- BNP Paribas Financial Markets's portfolio value fell 2.5% quarter-over-quarter to $54.9B.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2019, filed 12 Feb 2020.